Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Psychiatric Research

Background:

• Individual variability in drug metabolism influences treatment efficacy and adverse events.
• Schizophrenia treatment often involves antipsychotics like haloperidol, requiring careful dosage adjustments.
• Understanding metabolic ratios can predict drug disposition and potential side effects.

Purpose of the Study:

• To investigate the relationship between dextromethorphan/dextrorphan metabolic ratios and haloperidol pharmacokinetics.
• To determine if metabolic ratios correlate with the incidence of extrapyramidal side effects in schizophrenic patients.
• To explore the potential of phenotyping for predicting haloperidol plasma concentrations.

Main Methods:

• Eighteen schizophrenic patients were phenotyped using dextromethorphan.
• Dextromethorphan/dextrorphan metabolic ratios were determined before haloperidol treatment.
• Plasma haloperidol and reduced haloperidol concentrations were measured after 2 weeks of haloperidol administration using HPLC.

Main Results:

• Significant correlations were observed between metabolic ratios and plasma haloperidol concentrations, reduced haloperidol concentrations, and the reduced haloperidol/haloperidol ratio.
• Patients experiencing extrapyramidal side effects exhibited higher reduced haloperidol concentrations and reduced haloperidol/haloperidol ratios.
• A trend towards higher haloperidol concentrations and metabolic ratios was noted in patients with side effects.

Conclusions:

• Dextromethorphan/dextrorphan metabolic ratio phenotyping shows potential for predicting haloperidol plasma concentrations in schizophrenic patients.
• This phenotyping approach may assist clinicians in anticipating drug levels and managing side effects.
• Further research is warranted to validate phenotyping in predicting psychotropic drug metabolism in psychiatric populations.